Name: Paolo
Surname: Guarascio
Date of birth:06-03-1949
Place of birth: Cosenza (Italy)
Nationality: italian
Phone: +39-06-58703042; +39-06-45449094; 3483395227
Address: via dei Carraresi 18 M 00164 Rome Italy
e-mail: pguarascio@scamilloforlanini.rm.it
An experienced specialist in Infectious Diseases and Hepatologist M.D.
Extensive clinical work and research studies in Viral Hepatitis and Liver
Histopathology.
Clinical Focus: Infectious Diseases Consultation for Hospitalized Patients.
Diagnosis and treatment of chronic viral hepatitis, autoimmune hepatitis,
primary biliary cirrhosis, liver cirrhosis and HCC. Histopathology of liver
diseases.
Fluent in English both spoken and written.
Education
1974 – Medical Degree cum laude, University of Rome La Sapienza.
1977 - Specialty in Infectious and Parasitic Diseases, University of
Rome “La Sapienza”.
1979 - Specialty in Liver Pathology and Histology, University of Rome
“La Sapienza”.
1974-1977 Residency in Internal Medicine, University of Rome “La
Sapienza”.
1980-1982 Medical Research Fellow at King's College Hospital and
Medical School in London, Liver Unit. Director Dr. Roger Williams.
1985 – Master in laparoscopy, University of Padova.
1987 - Consultant in Infectious Diseases.
Professional experiences
• 1977–1986 Full-time attending physician at the National Institute
for Infectious Diseases Lazzaro Spallanzani-IRCCS, Rome, Italy.
• • 1986–on Tenured senior staff physician at the National Institute
for Infectious Diseases Lazzaro Spallanzani-IRCCS, Rome, Italy.
• 1990-1997 Clinical Director of the Centre for Infectious Diseases
of the Liver and biliary system, Nichola’s Green Hospital of Rome.
• 1998-2002 Coordinator of the Liver Unit, L. Spallanzani Hospital of
Rome.
• 2002-2007 Coordinator of the Center for Diagnosis and Treatment
of Chronic Hepatitis, S. Camillo-Forlanini Hospital of Rome.
Current Position
Tenured senior staff physician at the Department of Specialized
Medicine-Liver Unit, S. Camillo-Forlanini Hospital, Rome
Membership in scientific and professional organizations
• European Society for the Study of the Liver.
• AISF Italian Association Study of Liver
• Medical Academy “Lancisiana”.
Teaching experience
• 1974-77 Department of Internal Medicine, University of Rome “La
Sapienza”.
• 1986-00 Professor in the Hospital Medical School of Rome.
Publications
1.
Pellicelli AM, Romano M, Guarascio P, Vignally P. Which is the real efficacy of pegylated
interferon alpha 2a or 2b plus ribavirin in HCV infected patients with advanced fibrosis?
J Hepatol. 2012 Sep;57(3):704-5. doi: 10.1016/j.jhep.2012.03.008. Epub 2012 Apr 14.
2. Adriano M. Pellicelli, Giuseppe Barbaro, Claudio Puoti, Paolo Guarascio, Elena Angela
Lusi,
et al. Plasma Cytokines and Portopulmonary Hypertension in Patients With
Cirrhosis Waiting for Orthotopic Liver Transplantation. Angiology 2010 Nov;61(8):802-6.
3.
A.M. Pellicelli, P. Guarascio, C. D’Ambrosio, E.A. Lusi, R. Villani, et al. Portal Vein
Thrombosis in cirrhotic patients: Safety and Efficacy of low dosage of Enoxaparin.
Journal of Hepatology-Suppl N1 vol. 52 (2010)
4.
Lusi EA and Guarascio P. HIV vaccine. A short and concise query. Vaccine Feb 2,
2009 .
5.
Lusi EA, Passamano M, Guarascio P, Scarpa A and Schiavo L. Innovative
electrochemical approach foran early detection of microRNAs . Anal. Chem Feb 24,
2009.
6. Angelico M, Koehler-Horst B, Piccolo P, Angelico F, Gentile S, Francioso S, Tarquini
P, Vecchia RD, Ponti L, Pilleri G, Barlattani A, Grieco A, Soccorsi F, Guarascio P,
Demelia L, Sorbello O, Rossi Z, Forlini G, Zaru S, Bandiera F; SMIEC II Investigators.
Peginterferon alpha-2aand ribavirin versus peginterferon alpha-2a monotherapy in
early virological responders and peginterferon alpha-2a and ribavirin versu
peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological
nonresponders: the SMIEC II trial in naïve patients with chronic hepatitis C. Eur J
Gastroenterol Hepatol. 2008 Jul; 20 (7):680-7.
7. Lusi EA, Guarascio P., A target rash. Lancet. 2005 Feb 26;365 (9461):784s
8. Lusi E.A., Guarascio P., Presutti C. , Villani R, Pellicelli A. and Soccorsi F. One step
nested PCR for detection of 2 LTR circles in PBMCs of HIV-1 infected patients with no
detectable plasma HIV RNA. Journal of Virological Methods . 2005 Apr;125 (1):11-3.
9. Guarascio P, Lusi EA, Soccorsi F. Electronic muscular stimulators: A novel
unsuspected cause of rhabdomyolysis. Br. J. Sport Med. 2004
10. Unfavourable effects of colchicine in combination with interferon alpha in the treatment
of chronic hepatitis C. Angelico M. et al. Aliment Pharmacol Ther 2000: 14:1459-67
11. Visco G., Alba L., Grisetti S., Guarascio P., et al. Zidovudine plus interferon alfa-2b
treatment in patients with HIV and chronic active viral hepatitis. GUT
1993;supplement:S107-8.
12. Antonucci G., et al. Tuberculosis in HIV-infected subjects in Italy: a multicenter study.
AIDS 1992 6:1007-13.
13. Tocci G., et al. Long-term effects of recombinant leucocyte alpha interferon in the
treatment of chronic delta hepatitis. Arch Virol 1992 (suppl) 4: 306-307.
14. Antonucci G., et al. Tuberculosis and HIV infection in Italy. Chest 1991 vol 100 p.5
15. Tocci G., Conte A., Guarascio P., Visco G. Spontaneous remission of hepatocellular
carcinoma after massive gastrointestinal haemorrhage. BMJ 1990 641-2.
16. Girardi E., et al. B-cell function in hepatitis B virus-related liver cirrhosis: An in vitro
study. Viral Hepatitis and liver disease 1988, pp.656-659.
17. Guarascio P., et al. An open study of human lymphoblastoid interferon and oral
acyclovir in chronic hepatitis B virus infection. Journal of hepatology 1986,3(suppl.2)
s149-s153.
18. . Guarascio P., et al. Treatment of chronic HBeAg-positive patients with acyclovir. A
controlled trial. Journal of Hepatology 1986,3 (suppl.2) s143-s147.
19. . Guarascio P., et al. Liver damage from verapamil. BMJ 1984,288,362-363.
20. .Guarascio P., et al. Salmonella-associated diarrhoea and acid-base disturbances Italian
J. Gastroenterol. 1984,16,295-296.
21. Tedder R.S., Guarascio P. Production of monoclonal antibodies to hepatitis B surface
and core antigens, and use in the detection of viral antigens in liver biopsies. J.Hyg.
Camb. 1983,90,135-142.
22. .Guarascio P., et al. Liver damage with reversible portal hypertension from vitamin A
intoxication: demostration of ITO cells. J Clin Pathol 1983; 36, 769-771.
23. Guarascio P., et al. Value of copper-associated protein in diagnostic assement of liver
biopsy. J Clin Pathol 1983,36:18-23.
24. .Rossi-Fanelli F., et al. Branched-chain amino acids vs lactulose in the treatment of
hepatic coma. Digestive diseases and sciences 1982,vol27,929-935.
25. .De Felici AP., Guarascio P. Thymostimuline treatment in chronic active hepatitis.
Current Chemotherapy & Immunotherapy 1981,1205-1206.
26. . Visco G., et al. Chemotherapy in Salmonellosis. Current Chemotherapy 1978,161169.
27. . Abbate GF., et al. Diarrheal diseases. Current chemotherapy 1978, 165-6
28. Maggiore G, De Giacomo C, Balli F, Barbera C, Guarascio P, Nebbia
G, Palumbo M, Vajro P, Vegnente A. Which treatment for children with
hepatitis B surface antigen-positive chronic active hepatitis?J Pediatr
Gastroenterol Nutr. 1988 Sep-Oct;7(5):788-9.
Selected Correspondence and Oral Presentations.
1. Pellicelli A, et al. Influence of HCV Genotype 1a and Genotype 1b on the virological
response to antiviral therapy. September 2, 2010. Hepatology, vol-52 number 4 suppl
AASLD Abstracts.
2. Pellicelli A.et al. Entecavir for Lamivudine resistant HBV cirrhotic patients waiting for
OL T: viral and biochemical outcomes at one year. Hepatology October 2009 AASLD
Abstracts (444).
3. Angelico M. et al. Final results of the SMIEC TRIAL in naïve patients with hepatitis C:
Double Therapy (Peginterferon alfa2a+Ribavirin) vs Peginterferon monotherapy in early
viral responders and vs triple therapy (Peginterferon+Ribavirin+Amantadine) in early non
responders. Hepatology vol 42 Issue Supplement 1: 5 Oct 2005.
4. Alexander G., et al. Controlled trial of Acyclovir in chronic HBsAg, HBeAg positive
carriers. Journal of Hepatology 1985, s3.
5. M. Angelico et al. Colchicine worsens the efficacy of interferon alpha in patients with
chronic hepatitis. Hepatology October 1998. 21.
6. Callender ME., Et al. Hepatitis B virus markers in serum and liver of patients with
HBsAg negative chronic active hepatitis. In: The British Society of Gastroenterology
1982.35.
7. Guarascio P., et al. Treatment of HBeAg chronic hepatitis with Acyclovir. A controlled
trial. Hepatology 1988 vol.8 pp.1711-1719
8. Guarascio P. Treatment of chronic hepatitis B with interferon, Acyclovir and
prednisone. Italian Journal of Gastroenterology 1990 vol.22 No. 3 p.
9. Guarascio P., et al. Treatment of chronic hepatitis B: a single course of interferon
compared with a double course of interferon. A randomized controlled study.
International Symposium on viral hepatitis and liver diseases. Tokyo 1993 pg.149.
10. Longo MA., et T cell cytotoxicity in both liver tissue and circulating lymphocyte
subsets in chronic HBV active liver diseases. International Conference on infectious
diseases Cairo 1985:50
11. Guarascio P. et al.,: From Menghini Needle to present: Staging of Chronic Hepatitis.
In Medicine Meets Millennium, World Congress on Medicine and Health, Hannover,
Germany 21 July- 31 August 2000.
12. Guarascio P., et al. Mediterranean Spotted Fever. In Proceedings of the International
Congress for Infectious Diseases. Ed. Pozzi 1985, pp.287-292.
13. Guarascio P., et al. Treatment of chronic hepatitis B virus infection with interferon,
Acyclovir and prednisolone: two pilot studies. International Antiviral Symposium,
14. Montecarlo, 1987,pp.41-42.
15. . Fabiani F., L. Gasbarrone, P. Guarascio,: The primary biliary cirrhosis. "Acta of
Lancisiana Academy" XL-n.2.1996
16. . Guarascio P. Chronic viral hepatitis: diagnosis and histopathological classification.
Sorrento 9-11 October 1996.
17. Guarascio P., et al. Re-infection or reactivation of hepatitis B virus in HIV infection.
National Conference on AIDS and related syndromes. Naples Nov. 10-12. 1989: vol.I :
777-80
18. Altucci P., et al. Interferon in infectious diseases and cancer. Modern Therapy 1989
vol.3 107-121.
19. Galanti B., et al. Epidemiology and risk factors of acute viral hepatitis in Italy.
Multicenter study. Acta Mediterranean and tropical infectious disease. 1988 vol.7 ,5-10.
20. Boumis E., et al. Cellular immunity and clinical evolution of nAnB -chronic hepatitis
treated with interferon and thymostimuline. Liver : prevention and treatment.
1988:159-163.
21. Tocci G. et al. Human Leukocyte Alpha Interferon Treatment for Chronic Active. B
+DELTAHepatitis (B+D/CAH). Journal of Interferon Research, November 4,1987
22. .Guarascio P., et al. Is histological examination really useful? Proceedings of the
Lancisiana Academy, 1983 vol XXVII 167-177
23. Perroni L., P. Guarascio The biliary tract infections: Clinical, microbiologic and
Therapeutic Aspects. Lab. J. Res. Lab. Med .1979, vol2 149-159.
Books
• Paolo Guarascio VIRAL HEPATITIS 1990 Sedac first edition.
• Paolo Guarascio VIRAL HEPATITIS 1994 Sedac second edition.
• Paolo Guarascio CHRONIC HEPATITIS Infectious Diseases Medical books 1994.
Reviews
• Paolo Guarascio Chronic Hepatitis B: topical treatment. British Medical Journal,
Italian Ed. 1990 vol.12 :257-260.
Referees
Nikolai Naoumov, MD
Global Program Head
Novartis Pharma AG
Postfach
CH-4002 Basel
SWITZERLAND
Phone +41 61 3249325
Fax +41 61 3249439
Mobile +41795929281
nikolai.naoumov@novartis.com
www.novartis.com
-Prof. Giuseppe Visco (MD)
Former Consultant Physician
National Institute for Infectious Diseases
Lazzaro Spallanzani-IRCCS, Rome, Italy.*
giuseppevisco@fastwebnet.it
G.J. Alexander (MD)
Consultant Physician
Department of Hepatology
Cambridge University Hospitals
NHS Foundation Trust
Cambridge UK
Roma, 16.01.2014
Guarascio
Paolo